BioMarin Pharmaceutical Inc. (BMRN) Stock Score, Valuation & Financial Research
BioMarin Pharmaceutical Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 39/100.
Quick answer for BMRN
BioMarin Pharmaceutical Inc. currently has a Wall Street Score of 39/100. The stored market price is $64.73. Its financial score is 37/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What BioMarin Pharmaceutical Inc. does
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels. Also available are Brineura, a recombinant human t
BMRN financial snapshot
- Wall Street Score:
- 39/100
- Current price:
- $64.73
- Market capitalization:
- $12.51B
- Revenue:
- $3.41B
- Net income:
- $73.0M
- Free cash flow:
- $725.0M
- Cash:
- $874.0M
- Total debt:
- $4.20B
- EPS:
- 0.38
- P/E ratio:
- 170.3x
- Financial score:
- 37/100
- Valuation score:
- 0/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $725.0M, showing positive cash generation.
- The balance sheet shows $874.0M of cash versus $4.20B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BMRN increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 37/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BMRN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.